Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mepolizumab in Episodic Angioedema With Eosinophilia
NCT04128371Phase 2Terminated
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Jan 2021
- Primary completion
- Oct 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of mepolizumab in Episodic angioedema with eosinophilia (EAE), sponsored by National Institute of Allergy and Infectious Diseases. Started Jan 2021; status: terminated.
02
Drugs
mepolizumab
03
Conditions
Episodic angioedema with eosinophilia (EAE)
Beyond the preview
Go deeper on NCT04128371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04128371.